The Tariff Trump Hasn’t Tried Yet: A Market Access Charge on Foreign Capital Could Tame the Dollar and Boost U.S. Manufacturing
A Market Access Charge (MAC) might be the perfect addition to the tariff agenda; a surgical tool to tax capital inflows.
A Market Access Charge (MAC) might be the perfect addition to the tariff agenda; a surgical tool to tax capital inflows.
Depending on where you get your information, you would be forgiven for believing that we are getting buried by inflation, the stock market is in shambles, and that we need to start hoarding Chinese yuan to pay for our morning lattes.
The CPA Domestic Market Share Index (DMSI) dropped abruptly in the first quarter of 2025 as the massive pre-tariff import surge driven by stockpiling heavily outweighed current U.S. manufacturing output.
Following April’s trade deficit data, which showed a complete freefall in trade during the “Liberation Day” tariff month, May’s trade deficit rose by 18.7% on a monthly basis to $71.5 billion, according to the Bureau of Economic Analysis (BEA).
Tariffs were supposed to be inflationary, but so far, they’ve been proven wrong. Inflation over the last several months was not caused by 10% tariffs on Southeast Asia, nor by the short-lived 145% tariffs on China.
Last year, it wasn’t even in the Top 10. This year, they’re number one. General Motors was ranked as the most China-exposed U.S. multinational by Strategy Risks, a political risk consultancy in New York.
The U.S. kitchen cabinet industry has a long and storied history, deeply rooted in small- to medium-sized businesses that form the backbone of American manufacturing.
The two Trump Administrations have reshaped the debate on U.S. trade policy. For the first time in decades, U.S. officials are no longer endorsing the “free trade” orthodoxy that has contributed to the erosion of its manufacturing sector. Instead, tariffs are now the centerpiece of U.S. plans to repatriate supply chains and reindustrialize America.
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicine. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe.
A newly released report from the Congressional Budget Office (CBO) has upended the way policymakers should think about tariffs.